Cardiovascular Therapeutics

Edited by:

Jane E. Freedman, MD, Editor
Henry Krum, PhD, Editor
Chim C. Lang, MD, Editor

ISI Journal Citation Reports® Ranking: 2007: 40/74 CARDIAC & CARDIOVASCULAR SYSTEMS
Impact Factor: 1.738

---

Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) focuses on extensive reviews and original articles on the pharmacology and pharmacokinetics, toxicology, human investigation and clinical trials of new or potential cardiovascular drugs.
Articles in cardiovascular translational research, pharmacogenomics and personalized medicine, gene and cell therapies and pharmacoepidemiology are also encouraged.

TopNews and Announcements

Change of title for 2008
From the beginning of 2008 Cardiovascular Drug Reviews will be known as Cardiovascular Therapeutics, offering the following features:

•  Fast online publication via OnlineEarly
•  Manuscript Central electronic editorial office
•  Publication of original research articles 
• Freely available article content 

Online Content Now Available Back to Volume 1
All back issues of this journal are available online. Click here to browse contents and abstracts.  For further information on how to access these issues please visit our Librarian Site.

Support the public effort to prevent heart disease - the world's number one killer of men and women
In America alone, approximately 3,000 people die each day from cardiovascular disease. The Mysterious Human Heart explores the most common misconceptions about this unique organ and documents the latest scientific and medical revelations - discoveries that have already produced a startling decline in heart-related fatalities - and will help viewers understand the science behind what will keep their hearts healthy in the future.
For more information, please visit http://www.pbs.org/Heart
The Mysterious Human Heart, broadcast on PBS in October 2007,  is a co-production of David Grubin Productions and Thirteen/WNET New York in association with WETA Washington, D.C.  Funding is provided by Medtronic, AstraZeneca, and Mars, Incorporated - makers of CocoaVia.  Additional funding is provided by the Fannie E. Rippel Foundation.

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate,  please visit our policy statement. 

 

TopHighlights

Following are the most cited articles from Cardiovascular Drug Reviews as of 2006:  

1. A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist
   Wienen, W; Entzeroth, M; van Meel, JCA; Stangier, J; Busch, U; Ebner, T; Schmid, J; Lehmann, H; Matzek, K; Kempthorne-Rawson, J; Gladigau, V; Hauel, NH
2. Fondaparinux, a synthetic pentasaccharide: The first in a new class of antithrombotic agents - The selective factor Xa inhibitors
   Bauer, KA; Hawkins, DW; Peters, PC; Petitou, M; Herbert, JM; van Boeckel, CAA; Meuleman, DG
3. Eplerenone: A selective aldosterone receptor antagonist (SARA)
   Delyani, JA; Rocha, R; Cook, CS; Tolbert, DS; Levin, S; Roniker, B; Workman, DL; Sing, YLL; Whelihan, B
4. Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor
   Olsson, AG; McTaggart, F; Raza, A
5. Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
   Kajinami, K; Takekoshi, N; Saito, Y